Skip to main content
. 2023 Jun 7;28(12):1072–1078. doi: 10.1093/oncolo/oyad154

Table 2.

Incidence of end organ immune related adverse events in urothelial cancer patient cohort receiving immune-checkpoint inhibitors.

Variable Level N (%) = 70
Dermatologic irAE No 61 (87.1)
Yes 9 (12.9)
Missing 0
Neuropathy irAE No 14 (93.3)
Yes 1 (6.7)
Missing 55
Arthralgia irAE No 12 (80.0)
Yes 3 (20.0)
Missing 55
Gastrointestinal irAE No 14 (82.4)
Yes 3 (17.6)
Missing 53
Endocrine irAE No 12 (80.0)
Yes 3 (20.0)
Missing 55

Abbreviation: irAE, immune related adverse event.